Evidence map›Paper›PMID 33038525›Full record

ReviewDrug discovery today2021

3D engineering for optic neuropathy treatment.

Wenjing Xuan, Aji Alex Moothedathu, Tuo Meng, David C Gibson, Jinhua Zheng, Qingguo Xu

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug discovery today, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Cells · 2024
    Review
  2. Article
  3. Progress in the application of 3D printing technology in ophthalmology.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Wenjing XuanDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Aji Alex MoothedathuDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Tuo MengDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
David C GibsonSchool of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
Jinhua ZhengDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA; Department of Ophthalmology, Guizhou Medical University, Guiyang, Guizhou, China.
Qingguo XuDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA; Ophthalmology, Center for Pharmaceutical Engineering, Massey Cancer Center, and Institute for Structural Biology, Drug Discovery & Development (ISB3D), Virginia Commonwealth University, Richmond, VA 23298, USA. Electronic address: qxu@vcu.edu.
Virginia Commonwealth University · USGuiyang Medical University · CN

Funding

New method to treat or prevent corneal graft rejectionR01EY027827 · NEI · VIRGINIA COMMONWEALTH UNIVERSITY · PI XU, QINGGUO · 2017 to 2021
$2.0M
FDA HHS HHSF223201810114CNEI NIH HHS R01 EY027827
6 · The paper itself

Abstract

Ocular disorders, such as age-related macular degeneration (AMD), diabetic retinopathy (DR), retinitis pigmentosa (RP), and glaucoma, can cause irreversible visual loss, and affect the quality of life of millions of patients. However, only very few 3D systems can mimic human ocular pathophysiology, especially the retinal degenerative diseases, which involve the loss of retinal ganglion cells (RGCs), photoreceptors, or retinal pigment epithelial cells (RPEs). In this review, we discuss current progress in the 3D modeling of ocular tissues, and review the use of the aforementioned technologies for optic neuropathy treatment according to the categories of associated disease models and their applications in drug screening, mechanism studies, and cell and gene therapies.

Indexed as

Drug DesignEngineeringModels, BiologicalOptic Nerve DiseasesPrinting, Three-DimensionalRetinaCell- and Tissue-Based TherapyComputer SimulationHumans

Identifiers

PMID33038525
PMCPMC7854865
OpenAlexW3092277255

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.